Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates

Antimicrob Agents Chemother. 2014;58(2):1248-51. doi: 10.1128/AAC.02145-13. Epub 2013 Dec 9.

Abstract

MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Aspergillus / drug effects*
  • Aspergillus / growth & development
  • Aspergillus / metabolism
  • Candida / drug effects*
  • Candida / growth & development
  • Candida / metabolism
  • Drug Resistance, Fungal
  • Echinocandins / pharmacology
  • Glycosides / pharmacology*
  • Microbial Sensitivity Tests
  • Triterpenes / pharmacology*
  • beta-Glucans / antagonists & inhibitors
  • beta-Glucans / metabolism

Substances

  • Antifungal Agents
  • Echinocandins
  • Glycosides
  • Triterpenes
  • beta-Glucans
  • beta-1,3-glucan
  • ibrexafungerp